Cited by 164Inflammatory mediators and NSAID effectsAntiplatelet Therapy and Cardiovascular DiseasesEicosanoids and Hypertension Pharmacology

Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the Working Group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

Schmidt, Morten, Lamberts, Morten, Olsen, Anne-Marie Schjerning, Fosbøll, Emil, Niessner, Alexander, Tamargo, Juan, Rosano, Giuseppe, Agewall, Stefan +4 more·2016·European Heart Journal

Abstract

Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) have been used in clinical practice for more than a century and are among the most widely used drugs worldwide for the treatment of pain, fever, and inflammation.1,2 For decades, it has been known that many of these drugs can cause fluid retention and elevate blood pressure,3 thus increasing cardiovascular risk particularly in heart failure patients.4 However, the main worry in relation to the use of these agents has been gastrointestinal bleeding.5 Newer selective COX-2 inhibitors (coxibs) were developed as NSAIDs with reduced gastrointestinal toxicity, but retained analgesic and anti-inflammatory properties. Coxibs were tested in accordance to modern drug development regulations with large numbers of patients included in clinical trials. These trials demonstrated that rofecoxib,6–8 celecoxib,9 valdecoxib,10 and parecoxib10 increased the risk of cardiovascular complications. As a result, coxibs currently have very limited indications for use. Paradoxically, an older and relatively selective COX-2 inhibitor, diclofenac,11 continues to be one of the most widely used drugs worldwide and is in most countries sold over the counter.1 Mixed COX-1/COX-2 inhibitors such as ibuprofen and naproxen are also used widely and, without solid evidence, assumed to be safe. Given the current uncertainty regarding the safety of this class of agents and the rapidly accumulating data on their cardiovascular risks, this review summarizes the current evidence from randomized and observational studies on the cardiovascular safety of non-aspirin NSAIDs and presents a position for their use. Non-steroidal anti-inflammatory drugs exhibit their anti-inflammatory effect by inhibiting COX, which is the rate-limiting enzyme in prostaglandin synthesis ( Figure 1 ).12 There are …

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv505

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Non-steroidal anti-inflammatory drugs can increase the risk of progression of CHF as well as the frequency of adverse events, making their use controversial.

    “Conversely, non‐steroidal anti‐inflammatory drugs can increase the risk of progression of CHF as well as the frequency of adverse events, making its use controversial. 90”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., Lewis, B. S., & Torp-Pedersen, C.
Affiliations
  • Aarhus University Hospital (DK)
  • Gentofte Hospital (DK)
  • The Heart Centre, Copenhagen University Hospital Rigshospitalet 3 Department of Cardiology , , Copenhagen,
  • Medical University of Vienna (AT)
  • Universidad Complutense de Madrid (ES)
  • St George's Hospital (GB)
  • Oslo University Hospital (NO)
  • St George's, University of London (GB)
  • University of Copenhagen (DK)
  • Technion – Israel Institute of Technology (IL)
  • Aalborg University (DK)
Corresponding author
Schmidt, Morten
Venue
European Heart Journal
Published
2016-03-16
Volume
37
Issue
13
Pages
1015-1023
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2298123402
Cited by
164
References
83
Citations by year
2026: 11 · 2025: 13 · 2024: 9 · 2023: 14 · 2022: 21 · 2021: 13 · 2020: 16 · 2019: 24 · 2018: 18 · 2017: 17 · 2016: 6
FWCI
17.55
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Scopus (Elsevier) (submittedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
cardiovascular safety, cardiovascular risk, COX-2 inhibitors, rofecoxib, celecoxib, valdecoxib, parecoxib, diclofenac, ibuprofen, naproxen, gastrointestinal bleeding, heart failure, fluid retention, elevated blood pressure, cyclooxygenase inhibition, prostaglandin synthesis
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Atrial Fibrillation, Cardiovascular Diseases, Drug Therapy, Combination, Fibrinolytic Agents, Heart Failure, Hemostasis, Humans, Intraoperative Complications, Myocardial Infarction, Public Health, Risk Factors, Randomized Controlled Trials as Topic, Cyclooxygenase Inhibitors, Drug Approval, Risk Assessment, Safety-Based Drug Withdrawals, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review